We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: 13 PML Cases Confirmed in Tysabri Patients
FDA: 13 PML Cases Confirmed in Tysabri Patients
September 17, 2009
The FDA says there have been 13 confirmed cases of progressive multifocal leukoencephalopathy (PML) in patients taking Biogen Idec and Elan Pharmaceuticals’ Tysabri for multiple sclerosis (MS) in the past three years.